United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

4mmol) chewable tablets (trion pharma ltd - magnesium glycerophosphate - chewable tablet - 97.2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

4mmol) chewable tablets (essential-healthcare ltd - magnesium glycerophosphate - chewable tablet - 97.2mg

Israel - English - Ministry of Health

pharma shalom - aluminium oxide hydrated; dimethicone; magnesium hydroxide - chewable tablets - magnesium hydroxide 200 mg; dimethicone 25 mg; aluminium oxide hydrated 200 mg - combinations - antacid, antiflatulent, relief of sensation of heartburn.

Israel - English - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 500 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Israel - English - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Israel - English - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Ireland - English - HPRA (Health Products Regulatory Authority)

jntl consumer health i (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - h2-receptor antagonists; famotidine, combinations

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamotrigine - dispersible/chewable tablets - lamotrigine 25 mg - lamotrigine - lamotrigine - epilepsy• adults and adolescents aged 13 years and above- adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic-clonic seizures.- seizures associated with lennox-gastaut syndrome. lamictal is given as adjunctive therapy but may be the initial antiepileptic drug (aed) to start with in lennox-gastaut syndrome.• children and adolescents aged 2 to 12 years- adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome.- monotherapy of typical absence seizures.bipolar disorder• adults aged 18 years and above- prevention of depressive episodes in patients with bipolar i disorder who experience predominantly depressive episodes (see section 5.1).lamictal is not indicated for the acute treatment of manic or depressive episodes.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamotrigine - dispersible/chewable tablets - lamotrigine 100 mg - lamotrigine - lamotrigine - epilepsy• adults and adolescents aged 13 years and above- adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic-clonic seizures.- seizures associated with lennox-gastaut syndrome. lamictal is given as adjunctive therapy but may be the initial antiepileptic drug (aed) to start with in lennox-gastaut syndrome.• children and adolescents aged 2 to 12 years- adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome.- monotherapy of typical absence seizures.bipolar disorder• adults aged 18 years and above- prevention of depressive episodes in patients with bipolar i disorder who experience predominantly depressive episodes (see section 5.1).lamictal is not indicated for the acute treatment of manic or depressive episodes.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamotrigine - dispersible/chewable tablets - lamotrigine 50 mg - lamotrigine - lamotrigine - epilepsy• adults and adolescents aged 13 years and above- adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic-clonic seizures.- seizures associated with lennox-gastaut syndrome. lamictal is given as adjunctive therapy but may be the initial antiepileptic drug (aed) to start with in lennox-gastaut syndrome.• children and adolescents aged 2 to 12 years- adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome.- monotherapy of typical absence seizures.bipolar disorder• adults aged 18 years and above- prevention of depressive episodes in patients with bipolar i disorder who experience predominantly depressive episodes (see section 5.1).lamictal is not indicated for the acute treatment of manic or depressive episodes.